心臓再同期療法市場レポート：タイプ、用途、エンドユーザー、地域別、2023-2028年

概要

世界の心臓再同期療法（CRT）の市場規模は、2022年に54億米ドルに達しました。今後、IMARC Groupは、市場は2028年までに77億米ドルに達し、2022年から2028年の成長率（CAGR）は6.1%になると予測しています。心不全の有病率の上昇、政府・規制当局の支援の増加、有利な償還政策、新興国におけるヘルスケアインフラの拡大などが、市場を推進する主な要因となっています。

心臓再同期療法（CRT）は、特定の患者の心不全症状を治療するために用いられる高度な医療処置です。この治療には、ペースメーカーに似たCRT装置として知られる、外科的に胸部に埋め込む特殊な装置の使用が含まれます。この装置は、心臓の各室に電気的インパルスを送信することによって機能し、それによって各室の収縮を調整します。この同期によって心臓の効率が向上し、心不全にしばしば伴う疲労や息切れなどの症状が緩和されます。CRTは通常、最適な内科的治療と併用して、心臓内の電気的混乱が認められる中等度から重度の心不全患者に対して考慮されます。CRTの導入は、患者のQOLと全体的な機能能力を改善することを目的とした、心不全管理への的を絞ったアプローチを意味します。

特に新興経済諸国における急速なヘルスケア・インフラの開拓は、CRT機器の普及拡大に重要な役割を果たしており、予測期間中の市場成長を刺激するものと思われます。各国が医療施設の近代化、医療従事者の育成、ヘルスケアシステムの強化に投資する中、CRTのような専門的治療へのアクセスがより広まりつつあります。これに加え、患者が市場競争力のあるコストで高度な医療技術を提供する国で治療を受ける医療ツーリズムの増加も、市場成長を後押ししています。さらに、官民パートナーシップの増加により、CRTの資金調達と普及を目的とした政府と民間団体の協力関係が促進されています。また、教育キャンペーンや専門的なワークショップを通じて患者の認知度を高めることで、CRTの理解と受容が促進され、製品採用率が加速しています。さらに、製品開拓、マーケティング、流通におけるメーカー間の戦略的協力関係も市場の成長を支えています。このほか、費用対効果の高いCRTソリューションを提供する現地メーカーの出現が競合を助長し、治療をより身近なものにしているため、心臓再同期療法市場の成長を後押ししています。

心臓再同期療法（CRT）市場の動向と促進要因：

心不全の有病率の増加

世界の心不全発症率の上昇は、心臓再同期療法（CRT）市場の成長を促進する重要な要因です。心不全が、特に高齢化した人口集団や肥満や糖尿病の割合が増加した地域でより一般的になるにつれて、CRTのような効果的な治療法に対する需要が高まっています。CRTが特定の心不全患者の症状や全体的なQOLを改善する能力は、その重要性を強調しています。様々な公衆衛生上の取り組みも心不全の早期発見・早期治療を強調しており、CRTの必要性をさらに高めています。心不全という慢性疾患の有病率の増加により、治療ソリューションの継続的な進歩が必要とされており、CRTは現代の心不全管理戦略に不可欠な要素となっています。

急速な技術進歩

CRT分野における技術革新と進歩は、世界市場の成長に大きく寄与しています。主要企業による研究開発努力の増加は、CRTデバイスを継続的に改良し、その有効性、安全性、患者適合性を高めています。マルチポイントペーシングや適応アルゴリズムなどの技術革新により、より個別化された効率的な治療が可能になり、心不全患者の多様なニーズに対応しています。洗練された技術の統合により、他の医療システムや患者モニタリングツールとのシームレスな連携も容易になっています。このような技術の絶え間ない進化は、CRTが心不全治療の最前線であり続けることを保証しつつ、CRTの利点をより多くの患者層に拡大しつつあります。

政府・規制当局の支援

政府と規制当局の支援はCRT市場の形成に重要な役割を果たします。明確な規制の道筋を示すことで、各国政府は新しく改良されたCRTデバイスの迅速な承認を促進しています。また、多くの国が研究イニシアティブに投資し、この分野の技術革新を促進するために業界各社と協力しています。さらに、政府が支援する医療プログラムや政策は、心不全の負担軽減に重点を置いており、CRTのような治療法を支持しています。このように、心不全治療の強化を目的とした規制機関の連携は、成長を促進し、診療を標準化し、さまざまな医療システムでCRTを利用できるようにする上で有益な、献身的なアプローチを示しています。

心臓再同期療法（CRT）産業のセグメント化：

IMARC Groupは、世界の心臓再同期療法（CRT）市場レポートの各セグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国レベルの予測を提供しています。当レポートでは、市場をタイプ別、用途別、エンドユーザー別に分類しています。

本レポートで扱う主な質問

• 世界の心臓再同期療法（CRT）市場はこれまでどのように推移してきたのか？
• 世界の心臓再同期療法（CRT）市場における促進要因、抑制要因、機会は何か？
• それぞれの促進要因、抑制要因、機会が世界の心臓再同期療法（CRT）市場に与える影響は？
• 主要な地域市場は？
• 最も魅力的な心臓再同期療法（CRT）市場はどの国か？
• タイプ別の市場内訳は？
• 心臓再同期療法（CRT）市場で最も魅力的なタイプは？
• 用途別の市場内訳は？
• 心臓再同期療法（CRT）市場で最も魅力的な用途は？
• エンドユーザー別の市場内訳は？
• 心臓再同期療法（CRT）市場で最も魅力的なエンドユーザーは？
• 世界の心臓再同期療法（CRT）市場の競争構造は？
• 世界の心臓再同期療法（CRT）市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査目的
• 利害関係者
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要産業動向

第5章 心臓再同期療法（CRT）の世界市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：タイプ別

• CRT-除細動器
  • 市場動向
  • 市場展望
• CRTペースメーカー
  • 市場動向
  • 市場予測

第7章 市場内訳：用途別

• 心室内同期障害
  • 市場動向
  • 市場予測
• 心室間（V-V）同期障害
  • 市場動向
  • 市場予測
• 房室（A-V）同期異常
  • 市場動向
  • 市場予測

第8章 市場内訳：エンドユーザー別

• 病院
  • 市場動向
  • 市場予測
• 心臓センター
  • 市場動向
  • 市場予測
• 外来手術センター
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第9章 市場内訳：地域別

• 北米
  • 米国
    • 市場動向
    • 市場予測
  • カナダ
    • 市場動向
    • 市場予測
• アジア太平洋
  • 中国
    • 市場動向
    • 市場予測
  • 日本
    • 市場動向
    • 市場予測
  • インド
    • 市場動向
    • 市場予測
  • 韓国
    • 市場動向
    • 市場予測
  • オーストラリア
    • 市場動向
    • 市場予測
  • インドネシア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測
• 欧州
  • ドイツ
    • 市場動向
    • 市場予測
  • フランス
    • 市場動向
    • 市場予測
  • 英国
    • 市場動向
    • 市場予測
  • イタリア
    • 市場動向
    • 市場予測
  • スペイン
    • 市場動向
    • 市場予測
  • ロシア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測
• ラテンアメリカ
  • ブラジル
    • 市場動向
    • 市場予測
  • メキシコ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測
• 中東・アフリカ地域
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第10章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • LivaNova Plc
  • Medico S.p.A.
  • Medtronic Plc
  • Merit Medical Systems Inc.
  • MicroPort Scientific Corporation

List of Figures

• Figure 1: Global: Cardiac Resynchronization Therapy Market: Major Drivers and Challenges
• Figure 2: Global: Cardiac Resynchronization Therapy Market: Sales Value (in Billion US$), 2017-2022
• Figure 3: Global: Cardiac Resynchronization Therapy Market: Breakup by Type (in %), 2022
• Figure 4: Global: Cardiac Resynchronization Therapy Market: Breakup by Application (in %), 2022
• Figure 5: Global: Cardiac Resynchronization Therapy Market: Breakup by End User (in %), 2022
• Figure 6: Global: Cardiac Resynchronization Therapy Market: Breakup by Region (in %), 2022
• Figure 7: Global: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Billion US$), 2023-2028
• Figure 8: Global: Cardiac Resynchronization Therapy (CRT-Defibrillator) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 9: Global: Cardiac Resynchronization Therapy (CRT-Defibrillator) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 10: Global: Cardiac Resynchronization Therapy (CRT-Pacemaker) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 11: Global: Cardiac Resynchronization Therapy (CRT-Pacemaker) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 12: Global: Cardiac Resynchronization Therapy (Intraventricular Dyssynchrony) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 13: Global: Cardiac Resynchronization Therapy (Intraventricular Dyssynchrony) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 14: Global: Cardiac Resynchronization Therapy (Interventricular (V-V) Dyssynchrony) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 15: Global: Cardiac Resynchronization Therapy (Interventricular (V-V) Dyssynchrony) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 16: Global: Cardiac Resynchronization Therapy (Atrioventricular (A-V) Dyssynchrony) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 17: Global: Cardiac Resynchronization Therapy (Atrioventricular (A-V) Dyssynchrony) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 18: Global: Cardiac Resynchronization Therapy (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 19: Global: Cardiac Resynchronization Therapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 20: Global: Cardiac Resynchronization Therapy (Cardiac Centers) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 21: Global: Cardiac Resynchronization Therapy (Cardiac Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 22: Global: Cardiac Resynchronization Therapy (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 23: Global: Cardiac Resynchronization Therapy (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 24: Global: Cardiac Resynchronization Therapy (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
• Figure 25: Global: Cardiac Resynchronization Therapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 26: North America: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 27: North America: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 28: United States: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 29: United States: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 30: Canada: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 31: Canada: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 32: Asia Pacific: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 33: Asia Pacific: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 34: China: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 35: China: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 36: Japan: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 37: Japan: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 38: India: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 39: India: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 40: South Korea: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 41: South Korea: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 42: Australia: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 43: Australia: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 44: Indonesia: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 45: Indonesia: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 46: Others: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 47: Others: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 48: Europe: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 49: Europe: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 50: Germany: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 51: Germany: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 52: France: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 53: France: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 54: United Kingdom: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 55: United Kingdom: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 56: Italy: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 57: Italy: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 58: Spain: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 59: Spain: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 60: Russia: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 61: Russia: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 62: Others: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 63: Others: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 64: Latin America: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 65: Latin America: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 66: Brazil: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 67: Brazil: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 68: Mexico: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 69: Mexico: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 70: Others: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 71: Others: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 72: Middle East and Africa: Cardiac Resynchronization Therapy Market: Sales Value (in Million US$), 2017 & 2022
• Figure 73: Middle East and Africa: Cardiac Resynchronization Therapy Market Forecast: Sales Value (in Million US$), 2023-2028
• Figure 74: Global: Cardiac Resynchronization Therapy (CRT) Industry: SWOT Analysis
• Figure 75: Global: Cardiac Resynchronization Therapy (CRT) Industry: Value Chain Analysis
• Figure 76: Global: Cardiac Resynchronization Therapy (CRT) Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Cardiac Resynchronization Therapy Market: Key Industry Highlights, 2022 and 2028
• Table 2: Global: Cardiac Resynchronization Therapy Market Forecast: Breakup by Type (in Million US$), 2023-2028
• Table 3: Global: Cardiac Resynchronization Therapy Market Forecast: Breakup by Application (in Million US$), 2023-2028
• Table 4: Global: Cardiac Resynchronization Therapy Market Forecast: Breakup by End User (in Million US$), 2023-2028
• Table 5: Global: Cardiac Resynchronization Therapy Market Forecast: Breakup by Region (in Million US$), 2023-2028
• Table 6: Global: Cardiac Resynchronization Therapy Market Structure
• Table 7: Global: Cardiac Resynchronization Therapy Market: Key Players

Abstract

The global cardiac resynchronization therapy (CRT) market size reached US$ 5.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2022-2028. The rising prevalence of heart failure, increase in government and regulatory support, favorable reimbursement policies, and expansion of healthcare infrastructure in emerging economies are some of the major factors propelling the market.

Cardiac resynchronization therapy (CRT) is an advanced medical procedure used to treat heart failure symptoms in certain patients. This treatment involves the use of a specialized device that is surgically implanted in the chest, known as a CRT device, which is akin to a pacemaker. The device functions by transmitting electrical impulses to the chambers of the heart, thereby coordinating their contractions. This synchronization can enhance the heart's efficiency, alleviating symptoms such as fatigue and shortness of breath that often accompany heart failure. CRT is typically considered for individuals with moderate to severe heart failure who display evidence of electrical disarray within the heart, in conjunction with optimal medical therapy. The implementation of CRT signifies a targeted approach to heart failure management, aimed at improving the quality of life and overall functional capacity of patients.

Rapid healthcare infrastructure development, particularly in emerging economies, is playing a vital role in expanding the reach of CRT devices, which will stimulate market growth during the forecast period. As nations invest in modernizing medical facilities, training healthcare professionals, and strengthening healthcare systems, access to specialized treatments like CRT is becoming more widespread. This, coupled with a rise in medical tourism, where patients seek treatment in countries offering advanced healthcare technologies at competitive costs, is fueling the market growth. Furthermore, the increasing public-private partnerships are fostering collaborations between governments and private entities to finance and promote CRT. Enhanced patient awareness through educational campaigns and professional workshops is also facilitating the understanding and acceptance of CRT, accelerating the product adoption rate. In addition, strategic collaborations between manufacturers for product development, marketing, and distribution are supporting market growth. Besides this, the emergence of local manufacturers offering cost-effective CRT solutions is fostering competition and making therapy more accessible, thus propelling the growth of the cardiac resynchronization therapy market.

Cardiac Resynchronization Therapy (CRT) Market Trends/Drivers:

Increase in Prevalence of Heart Failure

The rising incidence of heart failure globally is a key factor driving the growth of the cardiac resynchronization therapy (CRT) market. As heart failure becomes more prevalent, particularly in aging populations and areas with increased rates of obesity and diabetes, the demand for effective treatments like CRT is escalating. The ability of CRT to improve symptoms and overall quality of life in selected patients with heart failure underscores its importance. Various public health initiatives are also emphasizing early detection and treatment of heart failure, further propelling the need for CRT. The growing prevalence of this chronic condition necessitates continuous advancement in therapeutic solutions, making CRT an integral part of contemporary heart failure management strategies.

Rapid Technological Advancements

Technological innovation and advancements in the field of CRT are contributing significantly to the growth of the global market. Increased research and development (R&D) efforts by key players are continuously refining CRT devices, enhancing their efficacy, safety, and patient compatibility. Innovations like multi-point pacing and adaptive algorithms are enabling more personalized and efficient therapies, catering to the diverse needs of heart failure patients. The integration of sophisticated technologies also facilitates seamless coordination with other medical systems and patient monitoring tools. This constant evolution in technology is extending the benefits of CRT to a wider patient demographic while ensuring that the therapy remains at the forefront of heart failure treatment.

Favorable Government and Regulatory Support

Government and regulatory support play a crucial role in shaping the CRT market. By providing clear regulatory pathways, governments are facilitating faster approvals of new and improved CRT devices. Many countries are also investing in research initiatives and collaborating with industry players to foster innovation in the field. Moreover, government-backed health programs and policies are focusing on reducing the burden of heart failure and are thus endorsing treatments like CRT. This alignment of regulatory bodies with the objective of enhancing heart failure care demonstrates a committed approach, which is instrumental in fostering growth, standardizing practices, and ensuring the accessibility of CRT across various healthcare systems.

Cardiac Resynchronization Therapy (CRT) Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cardiac resynchronization therapy (CRT) market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on type, application, and end user.

Breakup by Type:

CRT-Defibrillator

CRT-Pacemaker

CRT-Defibrillator represents the most popular type

The report has provided a detailed breakup and analysis of the market based on the type. This includes CRT-Defibrillator and CRT-Pacemaker. According to the report, CRT-Defibrillator represented the largest segment.

The CRT-Defibrillator (CRT-D) offers dual functionality in treating heart failure patients. Unlike standard CRT devices, CRT-D combines the features of cardiac resynchronization with defibrillation capabilities. This integrated approach enables the device to synchronize the heart's chambers, improving its efficiency, as well as to detect and correct life-threatening arrhythmias. By delivering a shock to the heart when it detects irregular rhythms, the CRT-D acts as a safeguard, adding an extra layer of protection for patients at high risk of sudden cardiac arrest. The all-encompassing nature of CRT-D extends its applicability, offering a comprehensive solution for managing both the chronic symptoms of heart failure and acute, critical arrhythmias. Additionally, improvements in device miniaturization, battery life, and programmability have contributed to its popularity. This consolidation of functions into one device, providing multifaceted care, has made CRT-D a preferred option, thus fueling the segment growth.

Breakup by Application:

Intraventricular Dyssynchrony

Interventricular (V-V) Dyssynchrony

Atrioventricular (A-V) Dyssynchrony

Intraventricular Dyssynchrony dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes intraventricular dyssynchrony interventricular (V-V) dyssynchrony, and atrioventricular (A-V) dyssynchrony. According to the report, intraventricular dyssynchrony represented the largest segment.

Intraventricular dyssynchrony refers to the uncoordinated contraction of the heart's ventricles, leading to inefficient pumping and worsening heart failure symptoms. This specific form of dyssynchrony has been identified in a significant number of heart failure patients, making it a primary target for CRT. The use of CRT in managing intraventricular dyssynchrony is well-established, offering marked improvements in both symptoms and overall cardiac function. The precise targeting and correction of this dyssynchrony through CRT enables the heart to pump more efficiently, enhancing the patient's quality of life and reducing hospitalization rates. Research studies and clinical trials have further supported the effectiveness of CRT in this application, solidifying its position as a standard treatment. The pervasive presence of intraventricular dyssynchrony among heart failure patients and the proven success of CRT in addressing this condition are fueling the segment growth.

Breakup by End User:

Hospitals

Cardiac Centers

Ambulatory Surgery Centers

Others

Hospitals hold the largest share in the market

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cardiac centers, ambulatory surgery centers, and others. According to the report, hospitals accounted for the largest market share.

Hospitals are often the primary setting for the diagnosis and treatment of heart failure, including the implantation and management of CRT devices. The complexity of CRT requires specialized equipment, skilled healthcare professionals, and coordinated post-procedure care, resources that hospitals are typically well-equipped to provide. Additionally, larger hospitals often have dedicated cardiac units with experts trained specifically in CRT, enabling comprehensive patient care from initial consultation through post-surgical monitoring. Many hospitals also engage in research and collaborate with device manufacturers, further aligning themselves with the advancements in CRT. The emphasis on integrated care pathways, coupled with the support of multi-disciplinary teams within the hospital setting, ensures that patients receive a seamless experience. This combination of resources, expertise, and patient-centric care is supporting the growth of the hospital segment.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share since the region boasts a sophisticated healthcare infrastructure, emphasis on medical innovation, and robust regulatory support that have fostered a favorable environment for the adoption and advancement of CRT. North America is also home to a significant number of leading medical research institutions and device manufacturers, promoting continuous innovation in CRT technology. In addition, high awareness levels among healthcare professionals and the general population about heart failure and its treatment options contribute to the growing acceptance of CRT. Moreover, the prevalence of lifestyle-related diseases leading to heart failure is relatively high in this region, creating a substantial patient base. Favorable reimbursement policies and insurance coverage further ease the accessibility of CRT for patients. These factors, along with the increasing focus on patient-centered care, position North America as the largest regional market for cardiac resynchronization therapy (CRT).

Competitive Landscape:

The market is experiencing steady growth as key players are actively engaged in research and development (R&D), striving to innovate and enhance CRT technology. Collaborating with healthcare institutions, they are focused on creating devices with improved efficiency, patient compatibility, and integration with other healthcare systems. Expansion into emerging markets and strategic alliances with local distributors are also part of their growth strategies. Through acquisitions and partnerships, these industry leaders are consolidating their presence, sharing expertise, and fostering technological advancements. Investments in clinical trials to validate new applications and continued engagement with regulatory bodies for compliance ensure alignment with global healthcare needs. We also expect the market to witness new entrants, consolidation of portfolios, and a rise in strategic collaborations to drive healthy competition within the CRT domain.

The market research report has provided a comprehensive analysis of the competitive landscape in the global cardiac resynchronization therapy (CRT) market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Biotronik SE & Co. KG

Boston Scientific Corporation

LivaNova Plc

Medico S.p.A.

Medtronic Plc

Merit Medical Systems Inc.

MicroPort Scientific Corporation

Recent Developments:

In July 2023, Biotronik SE & Co. KG announced the approval of its next-generation portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy (CRT) devices by the U.S. Food and Drug Administration (FDA).

Abbott Laboratories has made recent developments in cardiac resynchronization therapy (CRT) by releasing updates to its implantable pacemakers and defibrillators, showcasing its commitment to continuously improve patient care.

Key Questions Answered in This Report:

• How has the global cardiac resynchronization therapy (CRT) market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global cardiac resynchronization therapy (CRT) market?
• What is the impact of each driver, restraint, and opportunity on the global cardiac resynchronization therapy (CRT) market?
• What are the key regional markets?
• Which countries represent the most attractive cardiac resynchronization therapy (CRT) market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the cardiac resynchronization therapy (CRT) market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the cardiac resynchronization therapy (CRT) market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the cardiac resynchronization therapy (CRT) market?
• What is the competitive structure of the global cardiac resynchronization therapy (CRT) market?
• Who are the key players/companies in the global cardiac resynchronization therapy (CRT) market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cardiac Resynchronization Therapy (CRT) Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 CRT-Defibrillator
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 CRT-Pacemaker
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Intraventricular Dyssynchrony
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Interventricular (V-V) Dyssynchrony
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Atrioventricular (A-V) Dyssynchrony
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cardiac Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ambulatory Surgery Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Biotronik SE & Co. KG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Boston Scientific Corporation
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 LivaNova Plc
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Medico S.p.A.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 Medtronic Plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Merit Medical Systems Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 MicroPort Scientific Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio